Moderna Inc’s vaccine candidate against the coronavirus variant Omicron will be in clinical development over the next few weeks, and the company hopes to be able to share the data with regulators around March, CEO Stephane Bancel said. know on Monday.
“The vaccine is being worked on… it will be in the clinic in the coming weeks. We hope in the March time period there may be data to share with regulators to find out what’s going on. next step,” Bancel said at the World Economic Forum. Virtual Davos Agenda conference.
Moderna is also developing a booster-dose combination vaccine against COVID-19 with an experimental flu shot.
Bancel said the best-case scenario is that a combination COVID/flu vaccine will be available in the fall of 2023, at least in some countries.
“Our goal is to be able to have a booster shot every year so we don’t have compliance issues where people don’t want two to three shots a winter.”
Many countries have made a third dose of the COVID-19 vaccine available to their citizens, especially to the elderly and immunocompromised, while Israel has begun providing it to its citizens. his fourth dose.
In early January, Moderna’s CEO said people may need a fourth shot in the fall of 2022 as the booster’s effectiveness against COVID-19 is likely to decline over the next few months.
However, booster programs have been met with skepticism from some disease experts as to whether supplemental doses should be provided and how widely, including by the Union’s drug regulator. Europe, has expressed doubt about the need for a fourth booster dose.
Speaking at the same event, America’s top infectious disease expert Anthony Fauci said there was no evidence that repeated booster doses would overwhelm the immune system.
“Giving boosters at different times, there’s really no evidence of impeding (immune response).”
Fauci said the goal should be to have an enhancer that triggers a response against multiple potential variants.
(Reporting by Mrinalika Roy in Bengaluru Editing by Mark Potter)